patients eligible for treatment to 25-40 per cent. PDT has been shown significantly to decrease visual loss in patients with predominantly classic CNV in the macular area. However, even with laser treatment, there is a high risk of the recurrence of membrane growth and need for retreatment.
Injection Exudative AMD may also be amenable to treatment with drugs that inhibit vascular endothelial growth factor. Anecortave acetate is delivered by periocular injection, and pegaptanib sodium (Macugen) is an intraocular injection, requiring repeated doses. Most recently Ranibizumab (Lucentis) and Bevacizumab (Avastin) have produced improved vision in some patients.
Fig. 7.1
hlemorrhage in advanced AMD shown by red-free illumination.
Fig. 7.2
Choroidal neovascular membrane evident on fluorescein angiography.
